|
|
|
96TH GENERAL ASSEMBLY
State of Illinois
2009 and 2010 HB0527
Introduced 2/4/2009, by Rep. William B. Black SYNOPSIS AS INTRODUCED: |
|
225 ILCS 15/2 |
from Ch. 111, par. 5352 |
225 ILCS 15/4.1 new |
|
225 ILCS 15/4.2 new |
|
225 ILCS 15/4.3 new |
|
225 ILCS 15/4.4 new |
|
225 ILCS 15/4.5 new |
|
225 ILCS 15/4.6 new |
|
225 ILCS 15/15 |
from Ch. 111, par. 5365 |
225 ILCS 65/50-10 | was 225 ILCS 65/5-10 |
225 ILCS 85/3 |
from Ch. 111, par. 4123 |
225 ILCS 85/4 |
from Ch. 111, par. 4124 |
720 ILCS 570/102 |
from Ch. 56 1/2, par. 1102 |
|
Amends the Clinical Psychologist Licensing Act. Provides that the Clinical Psychologists
Licensing and Disciplinary Board shall grant certification as medical psychologists to doctoral level psychologists licensed under the Act who meet the additional education and training requirements under the Act, and that this certification shall grant medical psychologists prescriptive authority to prescribe and dispense those drugs used in the
treatment of mental, emotional, and psychological disorders. Sets forth provisions concerning the additional education and training requirements, application requirements, renewal, prescribing practices, controlled substance prescriptive authority, and State Board of Pharmacy interaction.
Amends the Nurse Practice Act, the Pharmacy Practice Act of 1987, and the Illinois Controlled Substances Act to make related changes.
|
| |
|
|
| FISCAL NOTE ACT MAY APPLY | |
|
|
A BILL FOR
|
|
|
|
|
HB0527 |
|
LRB096 04189 ASK 14231 b |
|
|
1 |
| AN ACT concerning regulation.
|
2 |
| Be it enacted by the People of the State of Illinois,
|
3 |
| represented in the General Assembly:
|
4 |
| Section 5. The Clinical Psychologist Licensing Act is |
5 |
| amended by changing Sections 2 and 15 and by adding Sections |
6 |
| 4.1, 4.2, 4.3, 4.4, 4.5, and 4.6 as follows:
|
7 |
| (225 ILCS 15/2) (from Ch. 111, par. 5352)
|
8 |
| (Section scheduled to be repealed on January 1, 2017)
|
9 |
| Sec. 2. Definitions. As used in this Act:
|
10 |
| (1) "Department" means the Department of Financial and
|
11 |
| Professional Regulation.
|
12 |
| (2) "Secretary" means the Secretary
of Financial and |
13 |
| Professional Regulation.
|
14 |
| (3) "Board" means the Clinical Psychologists Licensing
|
15 |
| and
Disciplinary
Board appointed by the Secretary.
|
16 |
| (4) "Person" means an individual, association, |
17 |
| partnership or corporation.
|
18 |
| (5) "Clinical psychology" means the independent
|
19 |
| evaluation, classification and treatment of mental, |
20 |
| emotional, behavioral
or nervous disorders or conditions, |
21 |
| developmental disabilities, alcoholism
and substance |
22 |
| abuse, disorders of habit or conduct, the psychological
|
23 |
| aspects of physical illness. The practice of clinical |
|
|
|
HB0527 |
- 2 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| psychology includes
psychoeducational evaluation, therapy, |
2 |
| remediation and consultation, the
use of psychological and |
3 |
| neuropsychological testing, assessment,
psychotherapy, |
4 |
| psychoanalysis, hypnosis, biofeedback, and behavioral
|
5 |
| modification when any of these are used for the purpose of |
6 |
| preventing or
eliminating psychopathology, or for the |
7 |
| amelioration of psychological
disorders of individuals or |
8 |
| groups. "Clinical psychology" does not include
the use of |
9 |
| hypnosis by unlicensed persons
pursuant to Section 3.
|
10 |
| (6) A person represents himself to be a "clinical |
11 |
| psychologist" within
the meaning of this Act when he or she |
12 |
| holds himself out to the public by
any title or description |
13 |
| of services incorporating the words "psychological",
|
14 |
| "psychologic", "psychologist", "psychology", or "clinical |
15 |
| psychologist" or
under such title or description offers to |
16 |
| render or renders clinical
psychological services as |
17 |
| defined in paragraph (7) of this Section to
individuals, |
18 |
| corporations, or the public for remuneration.
|
19 |
| (7) "Clinical psychological services" refers to any |
20 |
| services under
paragraph (5) of this Section if the words |
21 |
| "psychological", "psychologic",
"psychologist", |
22 |
| "psychology" or "clinical psychologist" are used to
|
23 |
| describe such services by the person or
organization |
24 |
| offering to render or rendering them.
|
25 |
| (8) "Drugs" has the meaning given to that term in the |
26 |
| Pharmacy Practice Act of 1987. |
|
|
|
HB0527 |
- 3 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (9) "Medicines" has the meaning given to that term in |
2 |
| the Pharmacy Practice Act of 1987. |
3 |
| (10) "Prescription" means an order for a drug, |
4 |
| laboratory test, or any medicines, devices, or
treatments, |
5 |
| including controlled substances, as defined
by State law. |
6 |
| (11) "Prescriptive authority" means the authority to |
7 |
| prescribe and dispense drugs, medicines, or other |
8 |
| treatment procedures. |
9 |
| (12) "Medical psychologist" means a licensed, doctoral |
10 |
| level psychologist who has undergone specialized training, |
11 |
| has passed an examination accepted by the Board, and has |
12 |
| received a current certificate granting prescriptive |
13 |
| authority that has not been revoked or suspended from the |
14 |
| Board. |
15 |
| This Act shall not apply to persons lawfully carrying on |
16 |
| their particular
profession or business under any valid |
17 |
| existing regulatory Act of the State.
|
18 |
| (Source: P.A. 94-870, eff. 6-16-06.)
|
19 |
| (225 ILCS 15/4.1 new) |
20 |
| (Section scheduled to be repealed on January 1, 2017) |
21 |
| Sec. 4.1. Medical psychologist certification; prescriptive |
22 |
| authority. The Board shall grant certification as medical |
23 |
| psychologists to doctoral level psychologists licensed under |
24 |
| this Act. This certification shall grant medical psychologists |
25 |
| prescriptive authority to prescribe and dispense those drugs |
|
|
|
HB0527 |
- 4 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| used in the
treatment of mental, emotional, and psychological |
2 |
| disorders
in accordance with applicable State and federal laws. |
3 |
| The Board shall develop and implement procedures and |
4 |
| criteria for reviewing educational and training credentials |
5 |
| for the certification process and the extent of prescriptive |
6 |
| authority, in accordance with current standards of |
7 |
| professional practice. The Board may seek the advice of other |
8 |
| State agencies with relevant experience in devising |
9 |
| certification procedures and criteria. |
10 |
| (225 ILCS 15/4.2 new) |
11 |
| (Section scheduled to be repealed on January 1, 2017) |
12 |
| Sec. 4.2. Medical psychologist certification application |
13 |
| requirements. |
14 |
| (a) The Department shall grant medical psychologist |
15 |
| certification to a psychologist who applies for certification |
16 |
| and demonstrates, by official transcript or other official |
17 |
| evidence satisfactory to the Board, all of the following: |
18 |
| (1) The completion of a doctoral program in psychology |
19 |
| from a regionally-accredited university or professional |
20 |
| school or, if the program is not accredited at the time of |
21 |
| graduation, completion of a doctoral program in psychology |
22 |
| that meets recognized acceptable professional standards, |
23 |
| as determined by the Board. |
24 |
| (2) Possession of a current and valid license to |
25 |
| practice psychology in this State. |
|
|
|
HB0527 |
- 5 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (3) The completion of an organized program of intensive |
2 |
| didactic instruction, as defined by the Board, within the |
3 |
| 5-year period immediately before the date of application, |
4 |
| consisting of a minimum of 300 contact hours and the |
5 |
| following core areas of instruction: |
6 |
| (A) neuroscience; |
7 |
| (B) pharmacology; |
8 |
| (C) psychopharmacology; |
9 |
| (D) physiology; |
10 |
| (E) pathophysiology; |
11 |
| (F) appropriate and relevant physical and |
12 |
| laboratory assessment; and |
13 |
| (G) clinical pharmacotherapeutics. |
14 |
| (4) The procurement of supervised and relevant |
15 |
| clinical experience sufficient to achieve competency in |
16 |
| the treatment of a diverse patient population under the |
17 |
| direction of qualified practitioners, as determined by the |
18 |
| Board, within the 5-year period immediately preceding the |
19 |
| date of application that includes the pharmacological |
20 |
| treatment of a minimum of 100 patients under the full |
21 |
| supervision and control of a designated qualified |
22 |
| practitioner who shall then certify the clinical |
23 |
| competency of the candidate for certification; and the |
24 |
| completion of
a minimum of 80 hours of supervised training |
25 |
| in physical
assessment under the full supervision and |
26 |
| control of a
designated qualified practitioner. |
|
|
|
HB0527 |
- 6 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (5) The successful completion of a certifying |
2 |
| examination stipulated by the Board. |
3 |
| (b) The Department shall grant certification to a |
4 |
| psychologist who applies for certification as a medical |
5 |
| psychologist and has completed the requirements specified in |
6 |
| subsection (a), except that the applicant has met the academic |
7 |
| requirements in paragraph (3) of subsection (a) more than 5 |
8 |
| years prior to the application for prescriptive authority, if |
9 |
| the applicant has completed 24 hours of continuing education in |
10 |
| the 2 years immediately prior to application, as specified in |
11 |
| Section 4.3 of this Act. |
12 |
| (225 ILCS 15/4.3 new) |
13 |
| (Section scheduled to be repealed on January 1, 2017) |
14 |
| Sec. 4.3. Renewal of medical psychologist certification. |
15 |
| (a) The Board shall establish by rule a method for the |
16 |
| annual renewal of medical psychologist certification at the |
17 |
| time of or in conjunction with the renewal of clinical |
18 |
| psychology licenses. |
19 |
| (b) Each applicant for renewal of medical psychologist |
20 |
| certification shall present satisfactory evidence to the Board |
21 |
| demonstrating the completion of 24 required hours of |
22 |
| instruction relevant to prescriptive authority during the 24 |
23 |
| months prior to application for renewal. |
24 |
| (225 ILCS 15/4.4 new) |
|
|
|
HB0527 |
- 7 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (Section scheduled to be repealed on January 1, 2017) |
2 |
| Sec. 4.4. Prescribing practices. |
3 |
| (a) Every prescription by a medical psychologist shall (i) |
4 |
| comply with all applicable State and federal laws, (ii) be |
5 |
| identified as issued by the psychologist as a "medical |
6 |
| psychologist", and (iii) include the medical psychologist's |
7 |
| identification number, as assigned by the Board. |
8 |
| (b) Records of all prescriptions shall be maintained in |
9 |
| patient records. |
10 |
| (c) A medical psychologist shall not delegate the |
11 |
| prescriptive authority to any other person. |
12 |
| (d) A medical psychologist shall maintain an ongoing |
13 |
| collaborative relationship with the health care practitioner |
14 |
| who oversees the patient's general medical care to ensure that |
15 |
| (i) necessary medical examinations are conducted, (ii) the |
16 |
| psychotropic medication is appropriate for the patient's |
17 |
| medical condition, (iii) and significant changes in the |
18 |
| patient's medical or psychological condition are discussed. |
19 |
| (e) In this Section: |
20 |
| "Collaborative relationship" means a cooperative |
21 |
| working relationship between a medical psychologist and a |
22 |
| health care practitioner in the provision of patient care, |
23 |
| including diagnosis and cooperation in the management and |
24 |
| delivery of physical and mental health care. |
25 |
| "Health care practitioner" means a physician, |
26 |
| osteopathic physician, or nurse practitioner. |
|
|
|
HB0527 |
- 8 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (225 ILCS 15/4.5 new) |
2 |
| (Section scheduled to be repealed on January 1, 2017) |
3 |
| Sec. 4.5. Controlled substance prescriptive authority. |
4 |
| (a) When authorized to prescribe controlled substances, a |
5 |
| medical psychologist shall file, in a timely manner, any |
6 |
| individual Drug Enforcement Agency (DEA) registrations and |
7 |
| identification numbers with the Board. |
8 |
| (b) The Board shall maintain current records of every |
9 |
| medical psychologist, including DEA registration and |
10 |
| identification numbers. |
11 |
| (225 ILCS 15/4.6 new) |
12 |
| (Section scheduled to be repealed on January 1, 2017) |
13 |
| Sec. 4.6. State Board of Pharmacy interaction. |
14 |
| (a) The Board shall transmit to the State Board of Pharmacy |
15 |
| an annual list of medical psychologists
containing the |
16 |
| following information: |
17 |
| (1) the name of the psychologist; |
18 |
| (2) the medical psychologist's identification number |
19 |
| assigned by the Board; and |
20 |
| (3) the effective dates of the medical psychologist's |
21 |
| certification. |
22 |
| (b) The Board shall promptly forward to the Board of |
23 |
| Pharmacy the names and titles of psychologists added to or |
24 |
| deleted from the annual list of medical psychologists. |
|
|
|
HB0527 |
- 9 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (c) The Board shall notify the State Board of Pharmacy, in |
2 |
| a timely manner, upon termination, suspension, or |
3 |
| reinstatement of a psychologist's certification as a medical |
4 |
| psychologist.
|
5 |
| (225 ILCS 15/15) (from Ch. 111, par. 5365)
|
6 |
| (Section scheduled to be repealed on January 1, 2017)
|
7 |
| Sec. 15. Disciplinary action; grounds. The Department may |
8 |
| refuse to
issue, refuse to renew, suspend,
or revoke any |
9 |
| license, or may place on probation, censure, reprimand, or
take |
10 |
| other disciplinary action deemed appropriate by the |
11 |
| Department,
including the imposition of fines not to exceed |
12 |
| $10,000 for each violation,
with regard to any license issued |
13 |
| under the provisions of this Act for any
one or a combination |
14 |
| of the following reasons:
|
15 |
| (1) Conviction of, or entry of a plea of guilty or nolo |
16 |
| contendere to, any crime that is a felony under the laws of
|
17 |
| the United
States or any state or territory thereof or that |
18 |
| is a misdemeanor
of which an
essential element is |
19 |
| dishonesty, or any crime that
is
directly
related to the |
20 |
| practice of the profession.
|
21 |
| (2) Gross negligence in the rendering of clinical |
22 |
| psychological
services.
|
23 |
| (3) Using fraud or making any misrepresentation in |
24 |
| applying for a license
or in passing the examination |
25 |
| provided for in this Act.
|
|
|
|
HB0527 |
- 10 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (4) Aiding or abetting or conspiring to aid or abet a |
2 |
| person, not a
clinical psychologist licensed under this |
3 |
| Act, in representing himself or
herself as
so licensed or |
4 |
| in applying for a license under this Act.
|
5 |
| (5) Violation of any provision of this Act or the rules |
6 |
| promulgated
thereunder.
|
7 |
| (6) Professional connection or association with any |
8 |
| person, firm,
association, partnership or corporation |
9 |
| holding himself, herself,
themselves, or
itself out in any |
10 |
| manner contrary to this Act.
|
11 |
| (7) Unethical, unauthorized or unprofessional conduct |
12 |
| as defined by rule.
In establishing those rules, the |
13 |
| Department shall consider, though is not
bound by, the |
14 |
| ethical standards for psychologists promulgated by |
15 |
| recognized
national psychology associations.
|
16 |
| (8) Aiding or assisting another person in violating any |
17 |
| provisions of this
Act or the rules promulgated thereunder.
|
18 |
| (9) Failing to provide, within 60 days, information in |
19 |
| response to a
written request made by the Department.
|
20 |
| (10) Habitual or excessive use or addiction to alcohol, |
21 |
| narcotics,
stimulants, or any other chemical agent or drug |
22 |
| that results in a
clinical
psychologist's inability to |
23 |
| practice with reasonable judgment, skill or
safety.
|
24 |
| (11) Discipline by another state, territory, the |
25 |
| District of Columbia or
foreign country, if at least one of |
26 |
| the grounds for the discipline is the
same or substantially |
|
|
|
HB0527 |
- 11 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| equivalent to those set forth herein.
|
2 |
| (12) Directly or indirectly giving or receiving from |
3 |
| any person, firm,
corporation, association or partnership |
4 |
| any fee, commission, rebate or
other form of compensation |
5 |
| for any professional service not actually or
personally |
6 |
| rendered.
|
7 |
| (13) A finding by the Board that the licensee, after
|
8 |
| having his or her
license placed on probationary status has |
9 |
| violated the terms of
probation.
|
10 |
| (14) Willfully making or filing false records or |
11 |
| reports, including but
not limited to, false records or |
12 |
| reports filed with State agencies or
departments.
|
13 |
| (15) Physical illness, including but not limited to, |
14 |
| deterioration through
the aging process, mental illness or |
15 |
| disability that results in
the inability to practice the |
16 |
| profession
with reasonable judgment, skill and safety.
|
17 |
| (16) Willfully failing to report an instance of |
18 |
| suspected child abuse or
neglect as required by the Abused |
19 |
| and Neglected Child Reporting Act.
|
20 |
| (17) Being named as a perpetrator in an indicated |
21 |
| report by the Department
of Children and Family Services |
22 |
| pursuant to the Abused and Neglected Child
Reporting Act, |
23 |
| and upon proof by clear and convincing evidence that the
|
24 |
| licensee has caused a child to be an abused child or |
25 |
| neglected child as defined
in the Abused and Neglected |
26 |
| Child Reporting Act.
|
|
|
|
HB0527 |
- 12 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (18) Violation of the Health Care Worker Self-Referral |
2 |
| Act.
|
3 |
| (19) Making a material misstatement in furnishing |
4 |
| information to the
Department, any other State or federal |
5 |
| agency, or any other entity.
|
6 |
| (20) Failing to report to the Department any adverse |
7 |
| judgment, settlement, or award arising from a liability |
8 |
| claim related to an act or conduct similar to an act or |
9 |
| conduct that would constitute grounds for action as set |
10 |
| forth in this Section. |
11 |
| (21) Failing to report to the Department any adverse |
12 |
| final action taken against a licensee or applicant by |
13 |
| another licensing jurisdiction, including any other state |
14 |
| or territory of the United States or any foreign state or |
15 |
| country, or any peer review body, health care institution, |
16 |
| professional society or association related to the |
17 |
| profession, governmental agency, law enforcement agency, |
18 |
| or court for an act or conduct similar to an act or conduct |
19 |
| that would constitute grounds for disciplinary action as |
20 |
| set forth in this Section.
|
21 |
| The entry of an order by any circuit court establishing |
22 |
| that any person
holding a license under this Act is subject to |
23 |
| involuntary admission or
judicial admission as provided for in |
24 |
| the Mental Health and Developmental
Disabilities Code, |
25 |
| operates as an automatic suspension of that license. That
|
26 |
| person may have his or her license restored only upon the |
|
|
|
HB0527 |
- 13 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| determination by
a circuit
court that the patient is no longer |
2 |
| subject to involuntary admission or
judicial admission and the |
3 |
| issuance of an order so finding and discharging the
patient and |
4 |
| upon the Board's recommendation to the
Department that the
|
5 |
| license be restored. Where the circumstances so indicate, the |
6 |
| Board may
recommend to the Department that it require an |
7 |
| examination prior to restoring
any license so automatically |
8 |
| suspended.
|
9 |
| The Department may refuse to issue or may suspend the |
10 |
| license of any person
who fails to file a return, or to pay the |
11 |
| tax, penalty or interest shown in
a filed return, or to pay any |
12 |
| final assessment of the tax penalty or
interest, as required by |
13 |
| any tax Act administered by the Illinois
Department of Revenue, |
14 |
| until such time as the requirements of any such tax
Act are |
15 |
| satisfied.
|
16 |
| In enforcing this Section, the Board upon a showing of a |
17 |
| possible
violation may compel any person licensed to practice |
18 |
| under this Act, or
who has applied for licensure or |
19 |
| certification pursuant to this Act, to submit
to a mental or |
20 |
| physical examination, or both, as required by and at the |
21 |
| expense
of the Department. The examining physicians or clinical |
22 |
| psychologists
shall be those specifically designated by the |
23 |
| Board.
The Board or the Department may order the examining |
24 |
| physician or clinical
psychologist to present testimony |
25 |
| concerning this mental or physical
examination
of the licensee |
26 |
| or applicant. No information shall be excluded by reason of
any |
|
|
|
HB0527 |
- 14 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| common law or statutory privilege relating to communications |
2 |
| between the
licensee or applicant and the examining physician |
3 |
| or clinical psychologist.
The person to be examined may have, |
4 |
| at his or her own expense, another
physician or clinical |
5 |
| psychologist of his or her choice present during all
aspects of |
6 |
| the examination. Failure of any person to submit to a mental or
|
7 |
| physical examination, when directed, shall be grounds for |
8 |
| suspension of a
license until the person submits to the |
9 |
| examination if the Board finds,
after notice and hearing, that |
10 |
| the refusal to submit to the examination was
without reasonable |
11 |
| cause.
|
12 |
| If the Board finds a person unable to practice because of |
13 |
| the reasons
set forth in this Section, the Board may require |
14 |
| that person to submit to
care, counseling or treatment by |
15 |
| physicians or clinical psychologists approved
or designated by |
16 |
| the Board, as a condition, term, or restriction for continued,
|
17 |
| reinstated, or
renewed licensure to practice; or, in lieu of |
18 |
| care, counseling or treatment,
the
Board may recommend to the |
19 |
| Department to file a complaint to immediately
suspend, revoke |
20 |
| or otherwise discipline the license of the person.
Any person |
21 |
| whose
license was granted, continued, reinstated, renewed, |
22 |
| disciplined or supervised
subject to such terms, conditions or |
23 |
| restrictions, and who fails to comply with
such terms, |
24 |
| conditions or restrictions, shall be referred to the Secretary |
25 |
| for a
determination as to whether the person shall have his or |
26 |
| her license
suspended immediately, pending a hearing by the |
|
|
|
HB0527 |
- 15 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| Board.
|
2 |
| In instances in which the Secretary immediately suspends a |
3 |
| person's license
under this Section, a hearing on that person's |
4 |
| license must be convened by
the Board within 15 days after the |
5 |
| suspension and completed without appreciable
delay.
The Board |
6 |
| shall have the authority to review the subject person's record |
7 |
| of
treatment and counseling regarding the impairment, to the |
8 |
| extent permitted by
applicable federal statutes and |
9 |
| regulations safeguarding the confidentiality of
medical |
10 |
| records.
|
11 |
| A person licensed under this Act and affected under this |
12 |
| Section shall
be
afforded an opportunity to demonstrate to the |
13 |
| Board that he or she can resume
practice in compliance with |
14 |
| acceptable and prevailing standards under the
provisions of his |
15 |
| or her license.
|
16 |
| The Board shall prescribe, by rule, criteria for |
17 |
| disciplining, suspending, or revoking the prescriptive |
18 |
| authority of a medical psychologist. The Board shall have the |
19 |
| power and duty to require remediation, suspension, or |
20 |
| revocation of a medical psychologist's certification for a |
21 |
| specified period of time determined by the Board. |
22 |
| (Source: P.A. 94-870, eff. 6-16-06.)
|
23 |
| Section 10. The Nurse Practice Act is amended by changing |
24 |
| Section 50-10 as follows:
|
|
|
|
HB0527 |
- 16 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (225 ILCS 65/50-10)
(was 225 ILCS 65/5-10)
|
2 |
| (Section scheduled to be repealed on January 1, 2018)
|
3 |
| Sec. 50-10. Definitions. Each of the following terms, when |
4 |
| used
in this Act, shall have the meaning ascribed to it in this |
5 |
| Section, except
where the context clearly indicates otherwise:
|
6 |
| "Academic year" means the customary annual schedule of |
7 |
| courses at a
college, university, or approved school, |
8 |
| customarily regarded as the school
year as distinguished from |
9 |
| the calendar year.
|
10 |
| "Advanced practice nurse" or "APN" means a person who has |
11 |
| met the qualifications for a (i) certified nurse midwife (CNM); |
12 |
| (ii) certified nurse practitioner (CNP); (iii) certified |
13 |
| registered nurse anesthetist (CRNA); or (iv) clinical nurse |
14 |
| specialist (CNS) and has been licensed by the Department. All |
15 |
| advanced practice nurses licensed and practicing in the State |
16 |
| of Illinois shall use the title APN and may use speciality |
17 |
| credentials after their name.
|
18 |
| "Approved program of professional nursing education" and |
19 |
| "approved
program of practical nursing education" are programs |
20 |
| of professional or
practical nursing, respectively, approved |
21 |
| by the Department under the
provisions of this Act.
|
22 |
| "Board" means the Board of Nursing appointed by the |
23 |
| Secretary. |
24 |
| "Collaboration" means a process involving 2 or more health |
25 |
| care professionals working together, each contributing one's |
26 |
| respective area of expertise to provide more comprehensive |
|
|
|
HB0527 |
- 17 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| patient care. |
2 |
| "Consultation" means the process whereby an advanced |
3 |
| practice nurse seeks the advice or opinion of another health |
4 |
| care professional. |
5 |
| "Credentialed" means the process of assessing and |
6 |
| validating the qualifications of a health care professional. |
7 |
| "Current nursing practice update course" means a planned |
8 |
| nursing education curriculum approved by the Department |
9 |
| consisting of activities that have educational objectives, |
10 |
| instructional methods, content or subject matter, clinical |
11 |
| practice, and evaluation methods, related to basic review and |
12 |
| updating content and specifically planned for those nurses |
13 |
| previously licensed in the United States or its territories and |
14 |
| preparing for reentry into nursing practice. |
15 |
| "Dentist" means a person licensed to practice dentistry |
16 |
| under the Illinois Dental Practice Act. |
17 |
| "Department" means the Department of Financial and |
18 |
| Professional Regulation. |
19 |
| "Impaired nurse" means a nurse licensed under this Act who |
20 |
| is unable to practice with reasonable skill and safety because |
21 |
| of a physical or mental disability as evidenced by a written |
22 |
| determination or written consent based on clinical evidence, |
23 |
| including loss of motor skills, abuse of drugs or alcohol, or a |
24 |
| psychiatric disorder, of sufficient degree to diminish his or |
25 |
| her ability to deliver competent patient care. |
26 |
| "License-pending advanced practice nurse" means a |
|
|
|
HB0527 |
- 18 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| registered professional nurse who has completed all |
2 |
| requirements for licensure as an advanced practice nurse except |
3 |
| the certification examination and has applied to take the next |
4 |
| available certification exam and received a temporary license |
5 |
| from the Department. |
6 |
| "License-pending registered nurse" means a person who has |
7 |
| passed the Department-approved registered nurse licensure exam |
8 |
| and has applied for a license from the Department. A |
9 |
| license-pending registered nurse shall use the title "RN lic |
10 |
| pend" on all documentation related to nursing practice. |
11 |
| "Physician" means a person licensed to practice medicine in |
12 |
| all its branches under the Medical Practice Act of 1987. |
13 |
| "Podiatrist" means a person licensed to practice podiatry |
14 |
| under the Podiatric Medical Practice Act of 1987.
|
15 |
| "Practical nurse" or "licensed practical nurse" means a |
16 |
| person who is
licensed as a practical nurse under this Act and |
17 |
| practices practical
nursing as defined in this Act. Only a |
18 |
| practical nurse
licensed under this Act is entitled to use the |
19 |
| title "licensed practical
nurse" and the abbreviation |
20 |
| "L.P.N.".
|
21 |
| "Practical nursing" means the performance of
nursing acts |
22 |
| requiring the basic nursing knowledge, judgement, and skill
|
23 |
| acquired by means of completion of an approved practical |
24 |
| nursing education
program. Practical nursing includes |
25 |
| assisting in the nursing process as
delegated by a registered |
26 |
| professional nurse or an advanced practice nurse. The
practical |
|
|
|
HB0527 |
- 19 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| nurse may work under the direction of a licensed physician, |
2 |
| dentist,
podiatrist, or other health care professional |
3 |
| determined by the Department.
|
4 |
| "Privileged" means the authorization granted by the |
5 |
| governing body of a healthcare facility, agency, or |
6 |
| organization to provide specific patient care services within |
7 |
| well-defined limits, based on qualifications reviewed in the |
8 |
| credentialing process.
|
9 |
| "Registered Nurse" or "Registered Professional Nurse" |
10 |
| means a person
who is licensed as a professional nurse under |
11 |
| this Act and practices
nursing as defined in
this Act. Only a |
12 |
| registered
nurse licensed under this Act is entitled to use the
|
13 |
| titles "registered nurse" and "registered professional nurse" |
14 |
| and the
abbreviation, "R.N.".
|
15 |
| "Registered professional nursing practice" is a scientific |
16 |
| process founded on a professional body of knowledge; it is a |
17 |
| learned profession based on the understanding of the human |
18 |
| condition across the life span and environment and
includes all
|
19 |
| nursing
specialities and means the performance of any nursing |
20 |
| act based upon
professional knowledge, judgment, and skills |
21 |
| acquired by means of completion
of an approved professional |
22 |
| nursing education program. A registered
professional nurse |
23 |
| provides holistic nursing care through the nursing process
to |
24 |
| individuals, groups, families, or communities, that includes |
25 |
| but is not
limited to: (1) the assessment of healthcare needs, |
26 |
| nursing diagnosis,
planning, implementation, and nursing |
|
|
|
HB0527 |
- 20 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| evaluation; (2) the promotion,
maintenance, and restoration of |
2 |
| health; (3) counseling, patient education,
health education, |
3 |
| and patient advocacy; (4) the administration of medications
and |
4 |
| treatments as prescribed by a physician licensed to practice |
5 |
| medicine in
all of its branches, a licensed dentist, a licensed |
6 |
| podiatrist, a medical psychologist, or a licensed
optometrist |
7 |
| or as prescribed by a physician assistant in accordance with
|
8 |
| written guidelines required under the Physician Assistant |
9 |
| Practice Act of 1987
or by an advanced practice nurse in |
10 |
| accordance with Article 65 of this Act; (5) the
coordination |
11 |
| and management of the nursing plan of care; (6) the delegation |
12 |
| to
and supervision of individuals who assist the registered |
13 |
| professional nurse
implementing the plan of care; and (7) |
14 |
| teaching nursing
students. The foregoing shall not be deemed to |
15 |
| include
those acts of medical diagnosis or prescription of |
16 |
| therapeutic or
corrective measures.
|
17 |
| "Professional assistance program for nurses" means a |
18 |
| professional
assistance program that meets criteria |
19 |
| established by the Board of Nursing
and approved by the |
20 |
| Secretary, which provides a non-disciplinary treatment
|
21 |
| approach for nurses licensed under this Act whose ability to |
22 |
| practice is
compromised by alcohol or chemical substance |
23 |
| addiction.
|
24 |
| "Secretary" means the Secretary of Financial and |
25 |
| Professional Regulation. |
26 |
| "Unencumbered license" means a license issued in good |
|
|
|
HB0527 |
- 21 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| standing. |
2 |
| "Written collaborative agreement" means a written |
3 |
| agreement between an advanced practice nurse and a |
4 |
| collaborating physician, dentist, or podiatrist pursuant to |
5 |
| Section 65-35.
|
6 |
| (Source: P.A. 95-639, eff. 10-5-07.)
|
7 |
| Section 15. The Pharmacy Practice Act is amended by |
8 |
| changing Sections 3 and 4 as follows:
|
9 |
| (225 ILCS 85/3) (from Ch. 111, par. 4123)
|
10 |
| (Section scheduled to be repealed on January 1, 2018)
|
11 |
| Sec. 3. Definitions. For the purpose of this Act, except |
12 |
| where otherwise
limited therein:
|
13 |
| (a) "Pharmacy" or "drugstore" means and includes every |
14 |
| store, shop,
pharmacy department, or other place where |
15 |
| pharmacist
care is
provided
by a pharmacist (1) where drugs, |
16 |
| medicines, or poisons are
dispensed, sold or
offered for sale |
17 |
| at retail, or displayed for sale at retail; or
(2)
where
|
18 |
| prescriptions of physicians, dentists, advanced practice |
19 |
| nurses, physician assistants, veterinarians, podiatrists, |
20 |
| medical psychologists, or
optometrists, within the limits of |
21 |
| their
licenses, are
compounded, filled, or dispensed; or (3) |
22 |
| which has upon it or
displayed within
it, or affixed to or used |
23 |
| in connection with it, a sign bearing the word or
words |
24 |
| "Pharmacist", "Druggist", "Pharmacy", "Pharmaceutical
Care", |
|
|
|
HB0527 |
- 22 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| "Apothecary", "Drugstore",
"Medicine Store", "Prescriptions", |
2 |
| "Drugs", "Dispensary", "Medicines", or any word
or words of |
3 |
| similar or like import, either in the English language
or any |
4 |
| other language; or (4) where the characteristic prescription
|
5 |
| sign (Rx) or similar design is exhibited; or (5) any store, or
|
6 |
| shop,
or other place with respect to which any of the above |
7 |
| words, objects,
signs or designs are used in any advertisement.
|
8 |
| (b) "Drugs" means and includes (l) articles recognized
in |
9 |
| the official United States Pharmacopoeia/National Formulary |
10 |
| (USP/NF),
or any supplement thereto and being intended for and |
11 |
| having for their
main use the diagnosis, cure, mitigation, |
12 |
| treatment or prevention of
disease in man or other animals, as |
13 |
| approved by the United States Food and
Drug Administration, but |
14 |
| does not include devices or their components, parts,
or |
15 |
| accessories; and (2) all other articles intended
for and having |
16 |
| for their main use the diagnosis, cure, mitigation,
treatment |
17 |
| or prevention of disease in man or other animals, as approved
|
18 |
| by the United States Food and Drug Administration, but does not |
19 |
| include
devices or their components, parts, or accessories; and |
20 |
| (3) articles
(other than food) having for their main use and |
21 |
| intended
to affect the structure or any function of the body of |
22 |
| man or other
animals; and (4) articles having for their main |
23 |
| use and intended
for use as a component or any articles |
24 |
| specified in clause (l), (2)
or (3); but does not include |
25 |
| devices or their components, parts or
accessories.
|
26 |
| (c) "Medicines" means and includes all drugs intended for
|
|
|
|
HB0527 |
- 23 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| human or veterinary use approved by the United States Food and |
2 |
| Drug
Administration.
|
3 |
| (d) "Practice of pharmacy" means (1) the interpretation and |
4 |
| the provision of assistance in the monitoring, evaluation, and |
5 |
| implementation of prescription drug orders; (2) the dispensing |
6 |
| of prescription drug orders; (3) participation in drug and |
7 |
| device selection; (4) drug administration limited to the |
8 |
| administration of oral, topical, injectable, and inhalation as |
9 |
| follows: in the context of patient education on the proper use |
10 |
| or delivery of medications; vaccination of patients 14 years of |
11 |
| age and older pursuant to a valid prescription or standing |
12 |
| order, by a physician licensed to practice medicine in all its |
13 |
| branches, upon completion of appropriate training, including |
14 |
| how to address contraindications and adverse reactions set |
15 |
| forth by rule, with notification to the patient's physician and |
16 |
| appropriate record retention, or pursuant to hospital pharmacy |
17 |
| and therapeutics committee policies and procedures; (5) drug |
18 |
| regimen review; (6) drug or drug-related research; (7) the |
19 |
| provision of patient counseling; (8) the practice of |
20 |
| telepharmacy; (9) the provision of those acts or services |
21 |
| necessary to provide pharmacist care; (10) medication therapy |
22 |
| management; and (11) the responsibility for compounding and |
23 |
| labeling of drugs and devices (except labeling by a |
24 |
| manufacturer, repackager, or distributor of non-prescription |
25 |
| drugs and commercially packaged legend drugs and devices), |
26 |
| proper and safe storage of drugs and devices, and maintenance |
|
|
|
HB0527 |
- 24 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| of required records. A pharmacist who performs any of the acts |
2 |
| defined as the practice of pharmacy in this State must be |
3 |
| actively licensed as a pharmacist under this Act.
|
4 |
| (e) "Prescription" means and includes any written, oral, |
5 |
| facsimile, or
electronically transmitted order for drugs
or |
6 |
| medical devices, issued by a physician licensed to practice |
7 |
| medicine in
all its branches, dentist, veterinarian, or |
8 |
| podiatrist, or
optometrist, within the
limits of their |
9 |
| licenses, by a physician assistant in accordance with
|
10 |
| subsection (f) of Section 4, or by an advanced practice nurse |
11 |
| in
accordance with subsection (g) of Section 4, containing the
|
12 |
| following: (l) name
of the patient; (2) date when prescription |
13 |
| was issued; (3) name
and strength of drug or description of the |
14 |
| medical device prescribed;
and (4) quantity, (5) directions for |
15 |
| use, (6) prescriber's name,
address
and signature, and (7) DEA |
16 |
| number where required, for controlled
substances.
DEA numbers |
17 |
| shall not be required on inpatient drug orders.
|
18 |
| (f) "Person" means and includes a natural person, |
19 |
| copartnership,
association, corporation, government entity, or |
20 |
| any other legal
entity.
|
21 |
| (g) "Department" means the Department of Financial and
|
22 |
| Professional Regulation.
|
23 |
| (h) "Board of Pharmacy" or "Board" means the State Board
of |
24 |
| Pharmacy of the Department of Financial and Professional |
25 |
| Regulation.
|
26 |
| (i) "Secretary"
means the Secretary
of Financial and |
|
|
|
HB0527 |
- 25 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| Professional Regulation.
|
2 |
| (j) "Drug product selection" means the interchange for a
|
3 |
| prescribed pharmaceutical product in accordance with Section |
4 |
| 25 of
this Act and Section 3.14 of the Illinois Food, Drug and |
5 |
| Cosmetic Act.
|
6 |
| (k) "Inpatient drug order" means an order issued by an |
7 |
| authorized
prescriber for a resident or patient of a facility |
8 |
| licensed under the
Nursing Home Care Act or the Hospital |
9 |
| Licensing Act, or "An Act in relation to
the founding and |
10 |
| operation of the University of Illinois Hospital and the
|
11 |
| conduct of University of Illinois health care programs", |
12 |
| approved July 3, 1931,
as amended, or a facility which is |
13 |
| operated by the Department of Human
Services (as successor to |
14 |
| the Department of Mental Health
and Developmental |
15 |
| Disabilities) or the Department of Corrections.
|
16 |
| (k-5) "Pharmacist" means an individual health care |
17 |
| professional and
provider currently licensed by this State to |
18 |
| engage in the practice of
pharmacy.
|
19 |
| (l) "Pharmacist in charge" means the licensed pharmacist |
20 |
| whose name appears
on a pharmacy license and who is responsible |
21 |
| for all aspects of the
operation related to the practice of |
22 |
| pharmacy.
|
23 |
| (m) "Dispense" or "dispensing" means the interpretation, |
24 |
| evaluation, and implementation of a prescription drug order, |
25 |
| including the preparation and delivery of a drug or device to a |
26 |
| patient or patient's agent in a suitable container |
|
|
|
HB0527 |
- 26 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| appropriately labeled for subsequent administration to or use |
2 |
| by a patient in accordance with applicable State and federal |
3 |
| laws and regulations.
"Dispense" or "dispensing" does not mean |
4 |
| the physical delivery to a patient or a
patient's |
5 |
| representative in a home or institution by a designee of a |
6 |
| pharmacist
or by common carrier. "Dispense" or "dispensing" |
7 |
| also does not mean the physical delivery
of a drug or medical |
8 |
| device to a patient or patient's representative by a
|
9 |
| pharmacist's designee within a pharmacy or drugstore while the |
10 |
| pharmacist is
on duty and the pharmacy is open.
|
11 |
| (n) "Nonresident pharmacy"
means a pharmacy that is located |
12 |
| in a state, commonwealth, or territory
of the United States, |
13 |
| other than Illinois, that delivers, dispenses, or
distributes, |
14 |
| through the United States Postal Service, commercially |
15 |
| acceptable parcel delivery service, or other common
carrier, to |
16 |
| Illinois residents, any substance which requires a |
17 |
| prescription.
|
18 |
| (o) "Compounding" means the preparation and mixing of |
19 |
| components, excluding flavorings, (1) as the result of a |
20 |
| prescriber's prescription drug order or initiative based on the |
21 |
| prescriber-patient-pharmacist relationship in the course of |
22 |
| professional practice or (2) for the purpose of, or incident |
23 |
| to, research, teaching, or chemical analysis and not for sale |
24 |
| or dispensing. "Compounding" includes the preparation of drugs |
25 |
| or devices in anticipation of receiving prescription drug |
26 |
| orders based on routine, regularly observed dispensing |
|
|
|
HB0527 |
- 27 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| patterns. Commercially available products may be compounded |
2 |
| for dispensing to individual patients only if all of the |
3 |
| following conditions are met: (i) the commercial product is not |
4 |
| reasonably available from normal distribution channels in a |
5 |
| timely manner to meet the patient's needs and (ii) the |
6 |
| prescribing practitioner has requested that the drug be |
7 |
| compounded.
|
8 |
| (p) (Blank).
|
9 |
| (q) (Blank).
|
10 |
| (r) "Patient counseling" means the communication between a |
11 |
| pharmacist or a pharmacy intern under the supervision of a |
12 |
| pharmacist and a patient or the patient's representative about |
13 |
| the patient's medication or device for the purpose of |
14 |
| optimizing proper use of prescription medications or devices. |
15 |
| "Patient counseling" may include without limitation (1) |
16 |
| obtaining a medication history; (2) acquiring a patient's |
17 |
| allergies and health conditions; (3) facilitation of the |
18 |
| patient's understanding of the intended use of the medication; |
19 |
| (4) proper directions for use; (5) significant potential |
20 |
| adverse events; (6) potential food-drug interactions; and (7) |
21 |
| the need to be compliant with the medication therapy. A |
22 |
| pharmacy technician may only participate in the following |
23 |
| aspects of patient counseling under the supervision of a |
24 |
| pharmacist: (1) obtaining medication history; (2) providing |
25 |
| the offer for counseling by a pharmacist or intern; and (3) |
26 |
| acquiring a patient's allergies and health conditions.
|
|
|
|
HB0527 |
- 28 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (s) "Patient profiles" or "patient drug therapy record" |
2 |
| means the
obtaining, recording, and maintenance of patient |
3 |
| prescription
information, including prescriptions for |
4 |
| controlled substances, and
personal information.
|
5 |
| (t) (Blank).
|
6 |
| (u) "Medical device" means an instrument, apparatus, |
7 |
| implement, machine,
contrivance, implant, in vitro reagent, or |
8 |
| other similar or related article,
including any component part |
9 |
| or accessory, required under federal law to
bear the label |
10 |
| "Caution: Federal law requires dispensing by or on the order
of |
11 |
| a physician". A seller of goods and services who, only for the |
12 |
| purpose of
retail sales, compounds, sells, rents, or leases |
13 |
| medical devices shall not,
by reasons thereof, be required to |
14 |
| be a licensed pharmacy.
|
15 |
| (v) "Unique identifier" means an electronic signature, |
16 |
| handwritten
signature or initials, thumb print, or other |
17 |
| acceptable biometric
or electronic identification process as |
18 |
| approved by the Department.
|
19 |
| (w) "Current usual and customary retail price" means the |
20 |
| price that a pharmacy charges to a non-third-party payor
.
|
21 |
| (x) "Automated pharmacy system" means a mechanical system |
22 |
| located within the confines of the pharmacy or remote location |
23 |
| that performs operations or activities, other than compounding |
24 |
| or administration, relative to storage, packaging, dispensing, |
25 |
| or distribution of medication, and which collects, controls, |
26 |
| and maintains all transaction information. |
|
|
|
HB0527 |
- 29 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (y) "Drug regimen review" means and includes the evaluation |
2 |
| of prescription drug orders and patient records for (1)
known |
3 |
| allergies; (2) drug or potential therapy contraindications;
|
4 |
| (3) reasonable dose, duration of use, and route of |
5 |
| administration, taking into consideration factors such as age, |
6 |
| gender, and contraindications; (4) reasonable directions for |
7 |
| use; (5) potential or actual adverse drug reactions; (6) |
8 |
| drug-drug interactions; (7) drug-food interactions; (8) |
9 |
| drug-disease contraindications; (9) therapeutic duplication; |
10 |
| (10) patient laboratory values when authorized and available; |
11 |
| (11) proper utilization (including over or under utilization) |
12 |
| and optimum therapeutic outcomes; and (12) abuse and misuse.
|
13 |
| (z) "Electronic transmission prescription" means any |
14 |
| prescription order for which a facsimile or electronic image of |
15 |
| the order is electronically transmitted from a licensed |
16 |
| prescriber to a pharmacy. "Electronic transmission |
17 |
| prescription" includes both data and image prescriptions.
|
18 |
| (aa) "Medication therapy management services" means a |
19 |
| distinct service or group of services offered by licensed |
20 |
| pharmacists, physicians licensed to practice medicine in all |
21 |
| its branches, advanced practice nurses authorized in a written |
22 |
| agreement with a physician licensed to practice medicine in all |
23 |
| its branches, or physician assistants authorized in guidelines |
24 |
| by a supervising physician that optimize therapeutic outcomes |
25 |
| for individual patients through improved medication use. In a |
26 |
| retail or other non-hospital pharmacy, medication therapy |
|
|
|
HB0527 |
- 30 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| management services shall consist of the evaluation of |
2 |
| prescription drug orders and patient medication records to |
3 |
| resolve conflicts with the following: |
4 |
| (1) known allergies; |
5 |
| (2) drug or potential therapy contraindications; |
6 |
| (3) reasonable dose, duration of use, and route of |
7 |
| administration, taking into consideration factors such as |
8 |
| age, gender, and contraindications; |
9 |
| (4) reasonable directions for use; |
10 |
| (5) potential or actual adverse drug reactions; |
11 |
| (6) drug-drug interactions; |
12 |
| (7) drug-food interactions; |
13 |
| (8) drug-disease contraindications; |
14 |
| (9) identification of therapeutic duplication; |
15 |
| (10) patient laboratory values when authorized and |
16 |
| available; |
17 |
| (11) proper utilization (including over or under |
18 |
| utilization) and optimum therapeutic outcomes; and |
19 |
| (12) drug abuse and misuse. |
20 |
| "Medication therapy management services" includes the |
21 |
| following: |
22 |
| (1) documenting the services delivered and |
23 |
| communicating the information provided to patients' |
24 |
| prescribers within an appropriate time frame, not to exceed |
25 |
| 48 hours; |
26 |
| (2) providing patient counseling designed to enhance a |
|
|
|
HB0527 |
- 31 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| patient's understanding and the appropriate use of his or |
2 |
| her medications; and |
3 |
| (3) providing information, support services, and |
4 |
| resources designed to enhance a patient's adherence with |
5 |
| his or her prescribed therapeutic regimens.
|
6 |
| "Medication therapy management services" may also include |
7 |
| patient care functions authorized by a physician licensed to |
8 |
| practice medicine in all its branches for his or her identified |
9 |
| patient or groups of patients under specified conditions or |
10 |
| limitations in a standing order from the physician. |
11 |
| "Medication therapy management services" in a licensed |
12 |
| hospital may also include the following: |
13 |
| (1) reviewing assessments of the patient's health |
14 |
| status; and |
15 |
| (2) following protocols of a hospital pharmacy and |
16 |
| therapeutics committee with respect to the fulfillment of |
17 |
| medication orders.
|
18 |
| (bb) "Pharmacist care" means the provision by a pharmacist |
19 |
| of medication therapy management services, with or without the |
20 |
| dispensing of drugs or devices, intended to achieve outcomes |
21 |
| that improve patient health, quality of life, and comfort and |
22 |
| enhance patient safety.
|
23 |
| (cc) "Protected health information" means individually |
24 |
| identifiable health information that, except as otherwise |
25 |
| provided, is:
|
26 |
| (1) transmitted by electronic media; |
|
|
|
HB0527 |
- 32 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (2) maintained in any medium set forth in the |
2 |
| definition of "electronic media" in the federal Health |
3 |
| Insurance Portability and Accountability Act; or |
4 |
| (3) transmitted or maintained in any other form or |
5 |
| medium. |
6 |
| "Protected health information" does not include individually |
7 |
| identifiable health information found in: |
8 |
| (1) education records covered by the federal |
9 |
| Family Educational Right and Privacy Act; or |
10 |
| (2) employment records held by a licensee in its |
11 |
| role as an employer. |
12 |
| (dd) "Standing order" means a specific order for a patient |
13 |
| or group of patients issued by a physician licensed to practice |
14 |
| medicine in all its branches in Illinois. |
15 |
| (ee) "Address of record" means the address recorded by the |
16 |
| Department in the applicant's or licensee's application file or |
17 |
| license file, as maintained by the Department's licensure |
18 |
| maintenance unit. |
19 |
| (ff) "Home pharmacy" means the location of a pharmacy's |
20 |
| primary operations.
|
21 |
| (Source: P.A. 94-459, eff. 1-1-06; 95-689, eff. 10-29-07.)
|
22 |
| (225 ILCS 85/4) (from Ch. 111, par. 4124)
|
23 |
| (Section scheduled to be repealed on January 1, 2018)
|
24 |
| Sec. 4. Exemptions. Nothing contained in any Section of |
25 |
| this Act shall
apply
to, or in any manner interfere with:
|
|
|
|
HB0527 |
- 33 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (a) the lawful practice of any physician licensed to |
2 |
| practice medicine in
all of its branches, dentist, podiatrist,
|
3 |
| veterinarian, medical psychologist, or therapeutically or |
4 |
| diagnostically certified optometrist within
the limits of
his |
5 |
| or her license, or prevent him or her from
supplying to his
or |
6 |
| her
bona fide patients
such drugs, medicines, or poisons as may |
7 |
| seem to him appropriate;
|
8 |
| (b) the sale of compressed gases;
|
9 |
| (c) the sale of patent or proprietary medicines and |
10 |
| household remedies
when sold in original and unbroken packages |
11 |
| only, if such patent or
proprietary medicines and household |
12 |
| remedies be properly and adequately
labeled as to content and |
13 |
| usage and generally considered and accepted
as harmless and |
14 |
| nonpoisonous when used according to the directions
on the |
15 |
| label, and also do not contain opium or coca leaves, or any
|
16 |
| compound, salt or derivative thereof, or any drug which, |
17 |
| according
to the latest editions of the following authoritative |
18 |
| pharmaceutical
treatises and standards, namely, The United |
19 |
| States Pharmacopoeia/National
Formulary (USP/NF), the United |
20 |
| States Dispensatory, and the Accepted
Dental Remedies of the |
21 |
| Council of Dental Therapeutics of the American
Dental |
22 |
| Association or any or either of them, in use on the effective
|
23 |
| date of this Act, or according to the existing provisions of |
24 |
| the Federal
Food, Drug, and Cosmetic Act and Regulations of the |
25 |
| Department of Health
and Human Services, Food and Drug |
26 |
| Administration, promulgated thereunder
now in effect, is |
|
|
|
HB0527 |
- 34 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| designated, described or considered as a narcotic,
hypnotic, |
2 |
| habit forming, dangerous, or poisonous drug;
|
3 |
| (d) the sale of poultry and livestock remedies in original |
4 |
| and unbroken
packages only, labeled for poultry and livestock |
5 |
| medication;
|
6 |
| (e) the sale of poisonous substances or mixture of |
7 |
| poisonous substances,
in unbroken packages, for nonmedicinal |
8 |
| use in the arts or industries
or for insecticide purposes; |
9 |
| provided, they are properly and adequately
labeled as to |
10 |
| content and such nonmedicinal usage, in conformity
with the |
11 |
| provisions of all applicable federal, state and local laws
and |
12 |
| regulations promulgated thereunder now in effect relating |
13 |
| thereto
and governing the same, and those which are required |
14 |
| under such applicable
laws and regulations to be labeled with |
15 |
| the word "Poison", are also labeled
with the word "Poison" |
16 |
| printed
thereon in prominent type and the name of a readily |
17 |
| obtainable antidote
with directions for its administration;
|
18 |
| (f) the delegation of limited prescriptive authority by a |
19 |
| physician
licensed to
practice medicine in all its branches to |
20 |
| a physician assistant
under Section 7.5 of the Physician |
21 |
| Assistant Practice Act of 1987. This
delegated authority under |
22 |
| Section 7.5 of the Physician Assistant Practice Act of 1987 may |
23 |
| but is not required to include prescription of
controlled |
24 |
| substances, as defined in Article II of the
Illinois Controlled |
25 |
| Substances Act, in accordance with written guidelines; and
|
26 |
| (g) The delegation of prescriptive authority by a physician
|
|
|
|
HB0527 |
- 35 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| licensed to practice medicine in all its branches to an |
2 |
| advanced practice
nurse in accordance with a written |
3 |
| collaborative
agreement under Section 65-35 of the Nurse |
4 |
| Practice Act. This authority, which is delegated under Section |
5 |
| 65-40 of the Nurse Practice Act, may but is not required to
|
6 |
| include the prescription of Schedule III, IV, or V controlled |
7 |
| substances as
defined
in Article II of the Illinois Controlled |
8 |
| Substances Act.
|
9 |
| (Source: P.A. 95-639, eff. 10-5-07 .)
|
10 |
| Section 20. The Illinois Controlled Substances Act is |
11 |
| amended by changing Section 102 as follows: |
12 |
| (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) |
13 |
| Sec. 102. Definitions. As used in this Act, unless the |
14 |
| context
otherwise requires:
|
15 |
| (a) "Addict" means any person who habitually uses any drug, |
16 |
| chemical,
substance or dangerous drug other than alcohol so as |
17 |
| to endanger the public
morals, health, safety or welfare or who |
18 |
| is so far addicted to the use of a
dangerous drug or controlled |
19 |
| substance other than alcohol as to have lost
the power of self |
20 |
| control with reference to his addiction.
|
21 |
| (b) "Administer" means the direct application of a |
22 |
| controlled
substance, whether by injection, inhalation, |
23 |
| ingestion, or any other
means, to the body of a patient, |
24 |
| research subject, or animal (as
defined by the Humane |
|
|
|
HB0527 |
- 36 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| Euthanasia in Animal Shelters Act) by:
|
2 |
| (1) a practitioner (or, in his presence, by his |
3 |
| authorized agent),
|
4 |
| (2) the patient or research subject at the lawful |
5 |
| direction of the
practitioner, or
|
6 |
| (3) a euthanasia technician as defined by the Humane |
7 |
| Euthanasia in
Animal Shelters Act.
|
8 |
| (c) "Agent" means an authorized person who acts on behalf |
9 |
| of or at
the direction of a manufacturer, distributor, or |
10 |
| dispenser. It does not
include a common or contract carrier, |
11 |
| public warehouseman or employee of
the carrier or warehouseman.
|
12 |
| (c-1) "Anabolic Steroids" means any drug or hormonal |
13 |
| substance,
chemically and pharmacologically related to |
14 |
| testosterone (other than
estrogens, progestins, and |
15 |
| corticosteroids) that promotes muscle growth,
and includes:
|
16 |
| (i) boldenone,
|
17 |
| (ii) chlorotestosterone,
|
18 |
| (iii) chostebol,
|
19 |
| (iv) dehydrochlormethyltestosterone,
|
20 |
| (v) dihydrotestosterone,
|
21 |
| (vi) drostanolone,
|
22 |
| (vii) ethylestrenol,
|
23 |
| (viii) fluoxymesterone,
|
24 |
| (ix) formebulone,
|
25 |
| (x) mesterolone,
|
26 |
| (xi) methandienone,
|
|
|
|
HB0527 |
- 37 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (xii) methandranone,
|
2 |
| (xiii) methandriol,
|
3 |
| (xiv) methandrostenolone,
|
4 |
| (xv) methenolone,
|
5 |
| (xvi) methyltestosterone,
|
6 |
| (xvii) mibolerone,
|
7 |
| (xviii) nandrolone,
|
8 |
| (xix) norethandrolone,
|
9 |
| (xx) oxandrolone,
|
10 |
| (xxi) oxymesterone,
|
11 |
| (xxii) oxymetholone,
|
12 |
| (xxiii) stanolone,
|
13 |
| (xxiv) stanozolol,
|
14 |
| (xxv) testolactone,
|
15 |
| (xxvi) testosterone,
|
16 |
| (xxvii) trenbolone, and
|
17 |
| (xxviii) any salt, ester, or isomer of a drug or |
18 |
| substance described
or listed in this paragraph, if |
19 |
| that salt, ester, or isomer promotes muscle
growth.
|
20 |
| Any person who is otherwise lawfully in possession of an |
21 |
| anabolic
steroid, or who otherwise lawfully manufactures, |
22 |
| distributes, dispenses,
delivers, or possesses with intent to |
23 |
| deliver an anabolic steroid, which
anabolic steroid is |
24 |
| expressly intended for and lawfully allowed to be
administered |
25 |
| through implants to livestock or other nonhuman species, and
|
26 |
| which is approved by the Secretary of Health and Human Services |
|
|
|
HB0527 |
- 38 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| for such
administration, and which the person intends to |
2 |
| administer or have
administered through such implants, shall |
3 |
| not be considered to be in
unauthorized possession or to |
4 |
| unlawfully manufacture, distribute, dispense,
deliver, or |
5 |
| possess with intent to deliver such anabolic steroid for
|
6 |
| purposes of this Act.
|
7 |
| (d) "Administration" means the Drug Enforcement |
8 |
| Administration,
United States Department of Justice, or its |
9 |
| successor agency.
|
10 |
| (e) "Control" means to add a drug or other substance, or |
11 |
| immediate
precursor, to a Schedule under Article II of this Act |
12 |
| whether by
transfer from another Schedule or otherwise.
|
13 |
| (f) "Controlled Substance" means a drug, substance, or |
14 |
| immediate
precursor in the Schedules of Article II of this Act.
|
15 |
| (g) "Counterfeit substance" means a controlled substance, |
16 |
| which, or
the container or labeling of which, without |
17 |
| authorization bears the
trademark, trade name, or other |
18 |
| identifying mark, imprint, number or
device, or any likeness |
19 |
| thereof, of a manufacturer, distributor, or
dispenser other |
20 |
| than the person who in fact manufactured, distributed,
or |
21 |
| dispensed the substance.
|
22 |
| (h) "Deliver" or "delivery" means the actual, constructive |
23 |
| or
attempted transfer of possession of a controlled substance, |
24 |
| with or
without consideration, whether or not there is an |
25 |
| agency relationship.
|
26 |
| (i) "Department" means the Illinois Department of Human |
|
|
|
HB0527 |
- 39 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| Services (as
successor to the Department of Alcoholism and |
2 |
| Substance Abuse) or its successor agency.
|
3 |
| (j) "Department of State Police" means the Department of |
4 |
| State
Police of the State of Illinois or its successor agency.
|
5 |
| (k) "Department of Corrections" means the Department of |
6 |
| Corrections
of the State of Illinois or its successor agency.
|
7 |
| (l) "Department of Professional Regulation" means the |
8 |
| Department
of Professional Regulation of the State of Illinois |
9 |
| or its successor agency.
|
10 |
| (m) "Depressant" or "stimulant substance" means:
|
11 |
| (1) a drug which contains any quantity of (i) |
12 |
| barbituric acid or
any of the salts of barbituric acid |
13 |
| which has been designated as habit
forming under section |
14 |
| 502 (d) of the Federal Food, Drug, and Cosmetic
Act (21 |
15 |
| U.S.C. 352 (d)); or
|
16 |
| (2) a drug which contains any quantity of (i) |
17 |
| amphetamine or
methamphetamine and any of their optical |
18 |
| isomers; (ii) any salt of
amphetamine or methamphetamine or |
19 |
| any salt of an optical isomer of
amphetamine; or (iii) any |
20 |
| substance which the Department, after
investigation, has |
21 |
| found to be, and by rule designated as, habit forming
|
22 |
| because of its depressant or stimulant effect on the |
23 |
| central nervous
system; or
|
24 |
| (3) lysergic acid diethylamide; or
|
25 |
| (4) any drug which contains any quantity of a substance |
26 |
| which the
Department, after investigation, has found to |
|
|
|
HB0527 |
- 40 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| have, and by rule
designated as having, a potential for |
2 |
| abuse because of its depressant or
stimulant effect on the |
3 |
| central nervous system or its hallucinogenic
effect.
|
4 |
| (n) (Blank).
|
5 |
| (o) "Director" means the Director of the Department of |
6 |
| State Police or
the Department of Professional Regulation or |
7 |
| his designated agents.
|
8 |
| (p) "Dispense" means to deliver a controlled substance to |
9 |
| an
ultimate user or research subject by or pursuant to the |
10 |
| lawful order of
a prescriber, including the prescribing, |
11 |
| administering, packaging,
labeling, or compounding necessary |
12 |
| to prepare the substance for that
delivery.
|
13 |
| (q) "Dispenser" means a practitioner who dispenses.
|
14 |
| (r) "Distribute" means to deliver, other than by |
15 |
| administering or
dispensing, a controlled substance.
|
16 |
| (s) "Distributor" means a person who distributes.
|
17 |
| (t) "Drug" means (1) substances recognized as drugs in the |
18 |
| official
United States Pharmacopoeia, Official Homeopathic |
19 |
| Pharmacopoeia of the
United States, or official National |
20 |
| Formulary, or any supplement to any
of them; (2) substances |
21 |
| intended for use in diagnosis, cure, mitigation,
treatment, or |
22 |
| prevention of disease in man or animals; (3) substances
(other |
23 |
| than food) intended to affect the structure of any function of
|
24 |
| the body of man or animals and (4) substances intended for use |
25 |
| as a
component of any article specified in clause (1), (2), or |
26 |
| (3) of this
subsection. It does not include devices or their |
|
|
|
HB0527 |
- 41 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| components, parts, or
accessories.
|
2 |
| (t-5) "Euthanasia agency" means
an entity certified by the |
3 |
| Department of Professional Regulation for the
purpose of animal |
4 |
| euthanasia that holds an animal control facility license or
|
5 |
| animal
shelter license under the Animal Welfare Act. A |
6 |
| euthanasia agency is
authorized to purchase, store, possess, |
7 |
| and utilize Schedule II nonnarcotic and
Schedule III |
8 |
| nonnarcotic drugs for the sole purpose of animal euthanasia.
|
9 |
| (t-10) "Euthanasia drugs" means Schedule II or Schedule III |
10 |
| substances
(nonnarcotic controlled substances) that are used |
11 |
| by a euthanasia agency for
the purpose of animal euthanasia.
|
12 |
| (u) "Good faith" means the prescribing or dispensing of a |
13 |
| controlled
substance by a practitioner in the regular course of |
14 |
| professional
treatment to or for any person who is under his |
15 |
| treatment for a
pathology or condition other than that |
16 |
| individual's physical or
psychological dependence upon or |
17 |
| addiction to a controlled substance,
except as provided herein: |
18 |
| and application of the term to a pharmacist
shall mean the |
19 |
| dispensing of a controlled substance pursuant to the
|
20 |
| prescriber's order which in the professional judgment of the |
21 |
| pharmacist
is lawful. The pharmacist shall be guided by |
22 |
| accepted professional
standards including, but not limited to |
23 |
| the following, in making the
judgment:
|
24 |
| (1) lack of consistency of doctor-patient |
25 |
| relationship,
|
26 |
| (2) frequency of prescriptions for same drug by one |
|
|
|
HB0527 |
- 42 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| prescriber for
large numbers of patients,
|
2 |
| (3) quantities beyond those normally prescribed,
|
3 |
| (4) unusual dosages,
|
4 |
| (5) unusual geographic distances between patient, |
5 |
| pharmacist and
prescriber,
|
6 |
| (6) consistent prescribing of habit-forming drugs.
|
7 |
| (u-1) "Home infusion services" means services provided by a |
8 |
| pharmacy in
compounding solutions for direct administration to |
9 |
| a patient in a private
residence, long-term care facility, or |
10 |
| hospice setting by means of parenteral,
intravenous, |
11 |
| intramuscular, subcutaneous, or intraspinal infusion.
|
12 |
| (v) "Immediate precursor" means a substance:
|
13 |
| (1) which the Department has found to be and by rule |
14 |
| designated as
being a principal compound used, or produced |
15 |
| primarily for use, in the
manufacture of a controlled |
16 |
| substance;
|
17 |
| (2) which is an immediate chemical intermediary used or |
18 |
| likely to
be used in the manufacture of such controlled |
19 |
| substance; and
|
20 |
| (3) the control of which is necessary to prevent, |
21 |
| curtail or limit
the manufacture of such controlled |
22 |
| substance.
|
23 |
| (w) "Instructional activities" means the acts of teaching, |
24 |
| educating
or instructing by practitioners using controlled |
25 |
| substances within
educational facilities approved by the State |
26 |
| Board of Education or
its successor agency.
|
|
|
|
HB0527 |
- 43 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (x) "Local authorities" means a duly organized State, |
2 |
| County or
Municipal peace unit or police force.
|
3 |
| (y) "Look-alike substance" means a substance, other than a |
4 |
| controlled
substance which (1) by overall dosage unit |
5 |
| appearance, including shape,
color, size, markings or lack |
6 |
| thereof, taste, consistency, or any other
identifying physical |
7 |
| characteristic of the substance, would lead a reasonable
person |
8 |
| to believe that the substance is a controlled substance, or (2) |
9 |
| is
expressly or impliedly represented to be a controlled |
10 |
| substance or is
distributed under circumstances which would |
11 |
| lead a reasonable person to
believe that the substance is a |
12 |
| controlled substance. For the purpose of
determining whether |
13 |
| the representations made or the circumstances of the
|
14 |
| distribution would lead a reasonable person to believe the |
15 |
| substance to be
a controlled substance under this clause (2) of |
16 |
| subsection (y), the court or
other authority may consider the |
17 |
| following factors in addition to any other
factor that may be |
18 |
| relevant:
|
19 |
| (a) statements made by the owner or person in control |
20 |
| of the substance
concerning its nature, use or effect;
|
21 |
| (b) statements made to the buyer or recipient that the |
22 |
| substance may
be resold for profit;
|
23 |
| (c) whether the substance is packaged in a manner |
24 |
| normally used for the
illegal distribution of controlled |
25 |
| substances;
|
26 |
| (d) whether the distribution or attempted distribution |
|
|
|
HB0527 |
- 44 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| included an
exchange of or demand for money or other |
2 |
| property as consideration, and
whether the amount of the |
3 |
| consideration was substantially greater than the
|
4 |
| reasonable retail market value of the substance.
|
5 |
| Clause (1) of this subsection (y) shall not apply to a |
6 |
| noncontrolled
substance in its finished dosage form that was |
7 |
| initially introduced into
commerce prior to the initial |
8 |
| introduction into commerce of a controlled
substance in its |
9 |
| finished dosage form which it may substantially resemble.
|
10 |
| Nothing in this subsection (y) prohibits the dispensing or |
11 |
| distributing
of noncontrolled substances by persons authorized |
12 |
| to dispense and
distribute controlled substances under this |
13 |
| Act, provided that such action
would be deemed to be carried |
14 |
| out in good faith under subsection (u) if the
substances |
15 |
| involved were controlled substances.
|
16 |
| Nothing in this subsection (y) or in this Act prohibits the |
17 |
| manufacture,
preparation, propagation, compounding, |
18 |
| processing, packaging, advertising
or distribution of a drug or |
19 |
| drugs by any person registered pursuant to
Section 510 of the |
20 |
| Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
|
21 |
| (y-1) "Mail-order pharmacy" means a pharmacy that is |
22 |
| located in a state
of the United States, other than Illinois, |
23 |
| that delivers, dispenses or
distributes, through the United |
24 |
| States Postal Service or other common
carrier, to Illinois |
25 |
| residents, any substance which requires a prescription.
|
26 |
| (z) "Manufacture" means the production, preparation, |
|
|
|
HB0527 |
- 45 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| propagation,
compounding, conversion or processing of a |
2 |
| controlled substance other than methamphetamine, either
|
3 |
| directly or indirectly, by extraction from substances of |
4 |
| natural origin,
or independently by means of chemical |
5 |
| synthesis, or by a combination of
extraction and chemical |
6 |
| synthesis, and includes any packaging or
repackaging of the |
7 |
| substance or labeling of its container, except that
this term |
8 |
| does not include:
|
9 |
| (1) by an ultimate user, the preparation or compounding |
10 |
| of a
controlled substance for his own use; or
|
11 |
| (2) by a practitioner, or his authorized agent under |
12 |
| his
supervision, the preparation, compounding, packaging, |
13 |
| or labeling of a
controlled substance:
|
14 |
| (a) as an incident to his administering or |
15 |
| dispensing of a
controlled substance in the course of |
16 |
| his professional practice; or
|
17 |
| (b) as an incident to lawful research, teaching or |
18 |
| chemical
analysis and not for sale.
|
19 |
| (z-1) (Blank).
|
20 |
| (aa) "Narcotic drug" means any of the following, whether |
21 |
| produced
directly or indirectly by extraction from substances |
22 |
| of natural origin,
or independently by means of chemical |
23 |
| synthesis, or by a combination of
extraction and chemical |
24 |
| synthesis:
|
25 |
| (1) opium and opiate, and any salt, compound, |
26 |
| derivative, or
preparation of opium or opiate;
|
|
|
|
HB0527 |
- 46 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (2) any salt, compound, isomer, derivative, or |
2 |
| preparation thereof
which is chemically equivalent or |
3 |
| identical with any of the substances
referred to in clause |
4 |
| (1), but not including the isoquinoline alkaloids
of opium;
|
5 |
| (3) opium poppy and poppy straw;
|
6 |
| (4) coca leaves and any salts, compound, isomer, salt |
7 |
| of an isomer,
derivative, or preparation of coca leaves |
8 |
| including cocaine or ecgonine,
and any salt, compound, |
9 |
| isomer, derivative, or preparation thereof which is
|
10 |
| chemically equivalent or identical with any of these |
11 |
| substances, but not
including decocainized coca leaves or |
12 |
| extractions of coca leaves which do
not contain cocaine or |
13 |
| ecgonine (for the purpose of this paragraph, the
term |
14 |
| "isomer" includes optical, positional and geometric |
15 |
| isomers).
|
16 |
| (bb) "Nurse" means a registered nurse licensed under the
|
17 |
| Nurse Practice Act.
|
18 |
| (cc) (Blank).
|
19 |
| (dd) "Opiate" means any substance having an addiction |
20 |
| forming or
addiction sustaining liability similar to morphine |
21 |
| or being capable of
conversion into a drug having addiction |
22 |
| forming or addiction sustaining
liability.
|
23 |
| (ee) "Opium poppy" means the plant of the species Papaver
|
24 |
| somniferum L., except its seeds.
|
25 |
| (ff) "Parole and Pardon Board" means the Parole and Pardon |
26 |
| Board of
the State of Illinois or its successor agency.
|
|
|
|
HB0527 |
- 47 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| (gg) "Person" means any individual, corporation, |
2 |
| mail-order pharmacy,
government or governmental subdivision or |
3 |
| agency, business trust, estate,
trust, partnership or |
4 |
| association, or any other entity.
|
5 |
| (hh) "Pharmacist" means any person who holds a license or |
6 |
| certificate of
registration as a registered pharmacist, a local |
7 |
| registered pharmacist
or a registered assistant pharmacist |
8 |
| under the Pharmacy Practice Act.
|
9 |
| (ii) "Pharmacy" means any store, ship or other place in |
10 |
| which
pharmacy is authorized to be practiced under the Pharmacy |
11 |
| Practice Act.
|
12 |
| (jj) "Poppy straw" means all parts, except the seeds, of |
13 |
| the opium
poppy, after mowing.
|
14 |
| (kk) "Practitioner" means a physician licensed to practice |
15 |
| medicine in all
its branches, dentist, optometrist, |
16 |
| podiatrist,
veterinarian, medical psychologist, scientific |
17 |
| investigator, pharmacist, physician assistant,
advanced |
18 |
| practice nurse,
licensed practical
nurse, registered nurse, |
19 |
| hospital, laboratory, or pharmacy, or other
person licensed, |
20 |
| registered, or otherwise lawfully permitted by the
United |
21 |
| States or this State to distribute, dispense, conduct research
|
22 |
| with respect to, administer or use in teaching or chemical |
23 |
| analysis, a
controlled substance in the course of professional |
24 |
| practice or research.
|
25 |
| (ll) "Pre-printed prescription" means a written |
26 |
| prescription upon which
the designated drug has been indicated |
|
|
|
HB0527 |
- 48 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| prior to the time of issuance.
|
2 |
| (mm) "Prescriber" means a physician licensed to practice |
3 |
| medicine in all
its branches, dentist, optometrist, |
4 |
| podiatrist , medical psychologist, or
veterinarian who issues a |
5 |
| prescription, a physician assistant who
issues a
prescription |
6 |
| for a Schedule III, IV, or V controlled substance
in accordance
|
7 |
| with Section 303.05 and the written guidelines required under |
8 |
| Section 7.5
of the
Physician Assistant Practice Act of 1987, or |
9 |
| an advanced practice
nurse with prescriptive authority |
10 |
| delegated under Section 65-40 of the Nurse Practice Act and in |
11 |
| accordance with Section 303.05
and a written
collaborative |
12 |
| agreement under Section 65-35 of the Nurse Practice Act.
|
13 |
| (nn) "Prescription" means a lawful written, facsimile, or |
14 |
| verbal order
of
a physician licensed to practice medicine in |
15 |
| all its branches,
dentist, podiatrist , medical psychologist, |
16 |
| or veterinarian for any controlled
substance, of an optometrist |
17 |
| for a Schedule III, IV, or V controlled substance in accordance |
18 |
| with Section 15.1 of the Illinois Optometric Practice Act of |
19 |
| 1987, of a physician assistant for a Schedule III, IV, or V
|
20 |
| controlled substance
in accordance with Section 303.05 and the |
21 |
| written guidelines required under
Section 7.5 of the
Physician |
22 |
| Assistant Practice Act of 1987, or of an advanced practice
|
23 |
| nurse with prescriptive authority delegated under Section |
24 |
| 65-40 of the Nurse Practice Act who issues a prescription for a |
25 |
| Schedule III, IV, or V
controlled substance in accordance
with
|
26 |
| Section 303.05 and a written collaborative agreement under |
|
|
|
HB0527 |
- 49 - |
LRB096 04189 ASK 14231 b |
|
|
1 |
| Section 65-35 of the Nurse Practice Act.
|
2 |
| (oo) "Production" or "produce" means manufacture, |
3 |
| planting,
cultivating, growing, or harvesting of a controlled |
4 |
| substance other than methamphetamine.
|
5 |
| (pp) "Registrant" means every person who is required to |
6 |
| register
under Section 302 of this Act.
|
7 |
| (qq) "Registry number" means the number assigned to each |
8 |
| person
authorized to handle controlled substances under the |
9 |
| laws of the United
States and of this State.
|
10 |
| (rr) "State" includes the State of Illinois and any state, |
11 |
| district,
commonwealth, territory, insular possession thereof, |
12 |
| and any area
subject to the legal authority of the United |
13 |
| States of America.
|
14 |
| (ss) "Ultimate user" means a person who lawfully possesses |
15 |
| a
controlled substance for his own use or for the use of a |
16 |
| member of his
household or for administering to an animal owned |
17 |
| by him or by a member
of his household.
|
18 |
| (Source: P.A. 94-556, eff. 9-11-05; 95-242, eff. 1-1-08; |
19 |
| 95-639, eff. 10-5-07; 95-689, eff. 10-29-07; 95-876, eff. |
20 |
| 8-21-08.)
|